Free shipping on all orders over $ 500

Recilisib

Cat. No. M11014
Recilisib Structure
Synonym:

ON 01210

Size Price Availability Quantity
5mg USD 105  USD105 In stock
10mg USD 142  USD142 In stock
25mg USD 230  USD230 In stock
50mg USD 400  USD400 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Recilisib (ON01210) is a radiation protection agent that activates the activity of AKT and PI3K in cells.

Chemical Information
Molecular Weight 336.79
Formula C16H13ClO4S
CAS Number 334969-03-8
Solubility (25°C) DMSO 30 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Juan Dong, et al. Dev Biol. Autophagy participates in germline cyst breakdown and follicular formation by modulating glycolysis switch via Akt signaling in newly-hatched chicken ovaries

[2] Reza Ahmadi, et al. Eur J Med Chem. Recent applications of vinyl sulfone motif in drug design and discovery

[3] Jie Liu, et al. Exp Ther Med. miR-15b, a diagnostic biomarker and therapeutic target, inhibits oesophageal cancer progression by regulating the PI3K/AKT signalling pathway

[4] Jiechun Huang, et al. Cell Biochem Funct. Overexpression of microRNA-23a-5p induces myocardial infarction by promoting cardiomyocyte apoptosis through inhibited of PI3K/AKT signalling pathway

[5] Y Zhang, et al. Eur Rev Med Pharmacol Sci. KRAS gene silencing inhibits the activation of PI3K-Akt-mTOR signaling pathway to regulate breast cancer cell epithelial-mesenchymal transition, proliferation and apoptosis

Related Akt Products
LY2780301

LY2780301 is an oral dual-target inhibitor of AKT/RSK that binds to and inhibits the activity of Akt, thereby inhibiting the PI3K/Akt signaling pathway, which in turn inhibits cell proliferation and induces apoptosis in tumor cells, and possesses antitumor activity.

Akt/SKG Substrate Peptide

Akt/SKG Substrate Peptide is a synthetic peptide suitable as a substrate for Akt/PKB, which is not phosphorylated by p70S6K or MAPK1.

Adropin (34-76) (human, mouse, rat)

Adropin (34-76) (human, mouse, rat) regulates fuel selection preferences in skeletal muscle.

Apoptin-derived peptide

Apoptin-derived peptide is an antitumor polypeptide with cytotoxicity.

TAT-TCL1-Akt-in

TAT-TCL1-Akt-in is an Akt inhibitor.

  Catalog
Abmole Inhibitor Catalog




Keywords: Recilisib, ON 01210 supplier, Akt, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.